Search results: (10000)
News INFOGRAPHIC: Post-Induction Therapy for AML – Current Guidelines
What are the recommended therapeutic modalities for consolidation and maintenance therapy of acute myeloid leukemia (AML) in patients over 60 years of age? We present a clear therapeutic algorithm according to the current recommendations of the American National Comprehensive Cancer Network.
News Can We Reach Brain Metastases of Lung Cancer with Anti-EGFR Targeted Therapy?
Information on the penetration of epidermal growth factor receptor tyrosine kinase inhibitors (anti-EGFR TKIs) through the blood-brain barrier primarily comes from preclinical testing. In clinical studies, its effectiveness in patients with brain metastases can be an indicator of its penetration. However, a truly robust analysis is lacking. Until one is available, we can preliminarily evaluate the available data.
News Case Study of a Patient with NSCLC − with Voting
Presented by: MUDr. Leona Koubková,
Pneumology Clinic, 2nd Faculty of Medicine, Charles University and Motol University Hospital in Prague
News Comparison of the Risk of Interstitial Lung Disease in Patients with RA with Biological and Targeted Disease-Modifying Antirheumatic Therapy
The authors of a newly published study sought to answer whether the risk of developing interstitial lung disease in patients with rheumatoid arthritis (RA) is affected by the administration of biological or targeted disease-modifying antirheumatic therapy. They analyzed data from more than 28,000 patients with RA.
News Fixed Combination of Tiotropium/Olodaterol in SMI Inhaler and Its Benefits in COPD Treatment
The TRONARTO study, whose conclusions were published in the International Journal of Chronic Obstructive Pulmonary Disease, addressed the issue of inhalation therapy in patients with chronic obstructive pulmonary disease (COPD). The authors focused on the effect of the combination of tiotropium and olodaterol in an SMI (soft mist inhaler) type inhaler.
News Finger on the Pulse of the Times with Automated Peritoneal Dialysis and Remote Patient Monitoring
The method of peritoneal dialysis brings many advantages to patients with chronic kidney disease and significantly eases their lives. Peritoneal dialysis saves time for both the patients themselves and the attending healthcare personnel. Modern medicine now offers an innovative tool that can remotely monitor the patient's condition, with the possibility of adjusting the treatment regimen.
News Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma − Data from real-world Czech practice
A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results of an observational study evaluating the addition of ixazomib to the combination with lenalidomide and dexamethasone in patients with relapsing/refractory multiple myeloma (RRMM). This involves experiences from real clinical practice, with data obtained from the Czech Registry of Monoclonal Gammopathies.
News Effect of Combination of Dorzolamide with Timolol for Wet Age-Related Macular Degeneration
In some eyes with wet age-related macular degeneration (AMD), exudation does not stop despite frequent intravitreal injections of vascular endothelial factor blockers (anti-VEGF). Adjuvant therapy that reduces edema may improve overall treatment outcomes concerning visual functions. A recently published multicenter randomized clinical study evaluated the effect of local therapy combining dorzolamide and timolol in patients with this issue.
News How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice
Modern antidiabetics – gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) – significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio- and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been shown by the prospective randomized EMPA-REG OUTCOME study and the real-world EMPRISE evaluation.
News Good news for sleep in patients with axial spondyloarthritis – ixekizumab effectively reduces night-time back pain
The targeted treatment of axial spondyloarthritis currently relies on the anti-inflammatory effects of tumor necrosis factor (TNF) inhibitors, interleukin IL-17 inhibitors, and Janus kinase (JAK) inhibitors. Besides the objective efficacy of these targeted treatments, it is crucial to describe their influence on subjective symptoms for decision-making in clinical practice. The evaluation of the analgesic effect of ixekizumab (IXE) was provided by the randomized controlled trial COAST-V.
News Efficacy of Luspatercept in 1st Line Treatment of Anemia Due to Low-Risk Myelodysplastic Syndrome
A planned interim analysis of the COMMANDS study showed a greater benefit of the innovative treatment with luspatercept compared to the established treatment with epoetin alfa in patients with anemia due to low-risk myelodysplastic syndrome (MDS) and untreated with erythropoiesis-stimulating agents (ESA). The results were published in June 2023 in the journal Lancet.
News ESC 2022: Evidence of SGLT2i Effectiveness in HFrEF Treatment is Growing: How to Integrate Them into Routine Practice?
Although the need for pharmacotherapeutic options for patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is essential, challenges in implementing this medication according to guidelines persist. This issue was also discussed at a symposium held as part of this year's European Society of Cardiology Congress (ESC 2022).
News Is Adding Fibrinogen Concentrate to Transfusion Therapy for Postpartum Hemorrhage an Effective Approach?
Significant postpartum hemorrhage can be managed with fresh frozen plasma transfusion. However, administering larger volumes is associated with several risks. The authors of the Japanese study below investigated whether fibrinogen concentrate added to fresh frozen plasma transfusions is an effective tool in reducing the need for erythrocyte concentrate and whether it helps prevent complications of intensive transfusion therapy.
News Efficacy and Safety of Levodopa/Entacapone/Carbidopa Combination in the Treatment of Advanced Parkinson's Disease – Prospective ELEGANCE Study
Therapy for advanced Parkinson's disease (PD) with a triple combination of levodopa/entacapone/carbidopa in the form of intestinal gel (LECIG) was first introduced to the Swedish market in 2018. The German team behind the ELEGANCE study aimed to gather available data and analyze the efficacy and safety of this modality in the long-term treatment of PD.
News Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population
Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does not spare individuals with hemophilia. According to epidemiological data, the prevalence of obesity is also increasing in this population, causing a number of complications in many health aspects.
News Third Generation Targeted Therapy for ROS1-Positive NSCLC
The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in preclinical studies against nearly all known mutations in the ALK and ROS1 genes that lead to resistance to crizotinib treatment. Moreover, lorlatinib crosses the blood-brain barrier, offering hope for patients with CNS metastases. The results of a clinical evaluation of the efficacy and safety of lorlatinib in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) were published in The Lancet Oncology.
News Contact Dermatitis in Patients with Venous Ulcers – and How to Prevent It?
The prevalence of chronic wounds increases with the rising average age, and for example, venous ulcers affect up to 2% of the global population. Materials used for wound coverage, however, present a risk for the development of contact dermatitis of allergic or irritant origin. The topic of contact dermatitis in patients with venous ulcers is covered in a review article published in the International Journal of Women’s Dermatology.
News Major Orthopedic Procedures in Patients with Inhibitor Treated with Emicizumab
Italian authors presented the results of a study of a small series of hemophilia patients with inhibitors treated with emicizumab, who underwent major orthopedic surgery, at the World Federation of Hemophilia (WFH) forum. This information is very important, as emicizumab, being a new drug, offers new perspectives on how to ensure surgery for these highly risky patients.
News Osimertinib in the Treatment of Patients with NSCLC with Secondary EGFR T790M Mutation – Case Study
Non-small cell lung cancer (NSCLC) is a genetically heterogeneous disease. Individualization of therapy based on the presence of specific tumor cell mutations is therefore crucial for choosing the optimal therapy for these patients. One of the targeted treatment options for patients with NSCLC with an activating mutation in the epidermal growth factor receptor (EGFR) gene is osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR TKI). We present a case study of a patient with NSCLC treated with osimertinib after disease progression due to a secondary EGFR T790M mutation resulting from afatinib therapy. The described case well illustrates the role of osimertinib in the treatment of NSCLC with secondary EGFR T790M mutation.
News Myths Accompanying Therapy of Arterial Hypertension
Arterial hypertension is among the most common yet most underestimated diseases in the adult population. Misinterpretation of data and inadequate management of this disease can be caused, among other things, by an excessive amount of available clinical data and its incorrect analysis. Insufficient control of blood pressure (BP) is, however, one of the most significant factors in increased cardiovascular (CV) mortality.
News INFOGRAPHIC: Mavacamten in the treatment of obstructive hypertrophic cardiomyopathy
Obstructive hypertrophic cardiomyopathy (HCM) is most commonly caused by disorders of cardiac muscle proteins. How does targeted treatment for this disease work? We bring a concise, graphically processed overview of the efficacy and mechanism of action of the first selective cardiac myosin inhibitor.
News 6 Years Follow-Up of Patients with Breast Cancer in the APHINITY Study
The primary analysis of results from the APHINITY clinical trial supported the combined anti-HER2 treatment with trastuzumab and pertuzumab in combination with chemotherapy in patients with early HER2-positive breast cancer. At the end of last year, efficacy and safety results of this treatment after more than 6 years of follow-up were presented.
News Current Data of Tofacitinib in the Treatment of IBD: What Improvements in Endoscopic and Histologic Outcomes Can Be Achieved?
The oral Janus kinase inhibitor (JAKi) tofacitinib is currently approved for the treatment of moderately to severely active ulcerative colitis (UC). Its efficacy and safety in this indication have previously been investigated in randomized placebo-controlled trials. However, the study discussed below examined the drug's impact on the endoscopic and histological progression of the disease and fecal calprotectin levels.